Exosome-carried microRNA-based signature as a cellular trigger for the evolution of chronic lymphocytic leukemia into Richter syndrome. (3rd October 2018)

• Record Type: Journal Article
• Authors: Jurj, Ancuta; Pop, Laura; Petrushev, Bobe; Pasca, Sergiu; Dima, Delia; Frinc, Ioana; Deak, Dalma; Desmirean, Minodora; Trifa, Adrian; Fetica, Bogdan; Gafencu, Grigore; Selicean, Sonia; Moisoiu, Vlad; Micu, Wilhelm-Thomas; Berce, Cristian; Sacu, Alexandra; Moldovan, Alin; Colita, Andrei; Bumbea, Horia; Tanase, Alina; Dascalescu, Angela; Zdrenghea, Mihnea; Stiufiuc, Rares; Leopold, Nicolae; Tetean, Romulus; Burzo, Emil; Tomuleasa, Ciprian; Berindan-Neagoe, Ioana
• Is Part Of: Critical reviews in clinical laboratory sciences. Volume 55:Number 7(2018)
• Page Start: 501
• Page End: 515
• Publication Date: 2018-10-03
• Subjects: Chronic lymphocytic leukemia -- microRNA -- prognostic -- Richter syndrome; Diagnosis, laboratory -- Periodicals; Medicine, Clinical -- Periodicals; 616.07
• DOI: 10.1080/10408363.2018.1499707
• Languages: English
• ISSNs: 1040-8363

Abstract

Abstract: Even if considered a cumulative and not a proliferative CD5+ B-cell neoplasm, chronic lymphocytic leukemia (CLL) has a proliferation rate higher than that recognized earlier, especially in the lymphoid tissues. Some patients with CLL develop a clinical syndrome entitled Richter syndrome (RS). Understanding CLL genetics and epigenetics may help to elucidate the molecular basics of the clinical heterogeneity of this type of malignancy. In the present project we aimed to identify a microRNA species that can predict the evolution of therapy-resistant CLL towards RS. In the first phase of our study, microRNA-19b was identified as a possible target, and in the second phase, we transfected three different CLL cell lines with microRNA-19b mimic and inhibitor and assessed the potential role on leukemia cells in vitro . The mechanism by which miR-19b acts were identified as the upregulation of Ki67 and downregulation of p53. This was further supported through RT-PCR and western blotting on CLL cell lines, as well as by next generation sequencing on two patients diagnosed with CLL that evolved into RS.